Read news on KRAS G12C with our app.
Read more in the app
KRAS G12C mutation identified as a rare potential target in genitourinary cancers
Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer - EurekAlert!
